An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

NCT05085964 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor decided to terminate the study early

Conditions

Retinitis Pigmentosa
Usher Syndrome Type 2

Interventions

DRUG: RNA antisense oligonucleotide for intravitreal injection

Sponsor

Laboratoires Thea

Collaborators

[object Object]